2,6-Dodecadienal, (2E,6Z)-
Common Name: |
2,6-Dodecadienal, (2E,6Z)- |
IUPAC Name: |
dodeca-2,6-dienal |
Molecular Formula: |
C13H20O |
SMILES: |
CCCCCC=CCCC=CC=O |
Inchi: |
1S/C12H20O/c1-2-3-4-5-6-7-8-9-10-11-12-13/h6-7,10-12H,2-5,8-9H2,1H3 |
Inchi Key: |
VPEGROOEBNSCCL-UHFFFAOYSA-N |
Cas No: |
21662-13-5 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
0 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
2 |
Name |
Value |
Molecular Weight (g/mol) |
192.30 |
Mass (g/mol) |
180.151 |
Molar Refractivity |
58.87 |
Net Charge |
|
HBD |
|
HBA |
1 |
Rt Bonds |
1 |
Rings |
|
TPSA |
9.23 |
Hetero Atoms |
1 |
Heavy Atoms |
14 |
Aromatic Heavy Atoms |
0 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
115.00 @ 0.10 mm Hg |
Vapor Pressure (mmHg@25.00 °C) |
0.008 |
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.85 |
LogP |
3.658 |
iLOGP |
2.97 |
XLOGP3 |
3.05 |
WLOGP |
3.22 |
MLOGP |
3.15 |
ESOL Log S |
-2.89 |
ESOL Solubility (mg/ml) |
0.249 |
ESOL Solubility (mol/l) |
0.001 |
ESOL Class: esol_class |
Soluble |
Ali Log S |
-2.91 |
Ali Solubility (mg/ml) |
0.24 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-2.37 |
Silicos-IT Solubility (mg/ml) |
0.82 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-5.31 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.914 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
1.829 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
1 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |